BIOCOM'S Lifelines: Funding the Cure: Foundations tread where investors won't
Winter 07
By Larry Edwards
When Robert J. Beall picked up the phone and called Aurora Biosciences in 1998, he was looking for a miracle – not just in terms of a life-saving drug, but in the very process of how drug development is funded.
